Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
2419600-41-1
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
gptkb:Mirati_Therapeutics
|
| gptkbp:hasApplication |
gptkb:cancer
|
| gptkbp:hasInChIKey |
QJQZQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasMolecularFormula |
C17H18ClN5O
|
| gptkbp:hasSMILES |
CC(C)N1C=NC2=C1C(=O)N(C(=N2)C)C3=CC=C(C=C3)Cl
|
| gptkbp:heldBy |
PRMT5 inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
MRTX1719
|
| gptkbp:indication |
solid tumors
|
| gptkbp:IUPACName |
(3S,6S)-6-(4-chlorophenyl)-3-methyl-1-(1-methylethyl)-3,6-dihydro-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one
|
| gptkbp:mechanismOfAction |
inhibits PRMT5-MTA complex
|
| gptkbp:PubChem_CID |
114442324
155349727 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational drug
|
| gptkbp:target |
PRMT5
|
| gptkbp:bfsParent |
gptkb:Mirati_Therapeutics
|
| gptkbp:bfsLayer |
7
|